Menu
Xsensio is aiming to become the world’s leading company in wearable systems that continuously monitor our physiological state to detect risks in real-time. To reach this ambitious goal, Xsensio has assembled a world-class team of experienced scientists, engineers and business developers, all committed to making the Lab-on-SkinTM a daily reality impacting tomorrow’s healthcare.
To discuss collaboration opportunities: please contact us at info [at] xsensio [dot] com.
Esmeralda is the CEO of Xsensio, a company she co-founded a few years ago. Prior to Xsensio, she had several years of experience as manager at Boston-based investment firm Commons Capital where she was in charge of screening investment opportunities in a partnership with the Bill and Melinda Gates Foundation. She earned her MBA at the Massachusetts Institute of Technology (MIT), a B.S. and M.S. in Economics from ULB, Belgium and an executive degree in management from EPFL.
Esmeralda is the CEO of Xsensio, a company she co-founded a few years ago. Prior to Xsensio, she had several years of experience as manager at Boston-based investment firm Commons Capital where she was in charge of screening investment opportunities in a partnership with the Bill and Melinda Gates Foundation. She earned her MBA at the Massachusetts Institute of Technology (MIT), a B.S. and M.S. in Economics from ULB, Belgium and an executive degree in management from EPFL.
Adrian is a co-founder of Xsensio, and its CSO. He is also a full Professor at EPFL, where he leads the Nanolab. He received his Ph.D. degree from the National Polytechnic Institute of Grenoble in France, and has held staff and/or visiting positions at LETI-CEA and LPCS-ENSER in Grenoble, at Stanford University, and at Tokyo Tech. He has published more than 350 articles in international journals and conference.
Fabien is working on the development of Xsensio’s microfluidics. After earning a M.S. in Physics at ETH Zurich, he accomplished a PhD and a post-doc in Nanofluidics at the Institute of Microengineering of EPFL. He was a visiting researcher at Lawrence Berkeley National Laboratory (LBL), United States for 3 months.
Johan is working on developing a library of biochemical applications for Xsensio. He earned his PhD in Physics and Chemistry from the Charles Sadron Institute / International Research Training Group (IRTG) Soft Matter Science in France. He then completed his post-doc in the Soft Matter Laboratory (SMaL) at EPFL, where he designed and elaborated mechano-sensitive polymeric microcapsules using microfluidics, and developed double@emulsion systems using tailor-made block co-polymer surfactants.
Aristea is working on expanding the company’s proprietary Lab-on-Skin™ sensing platform to new applications. She earned her PhD in Molecular Biology and Medical Biotechnology from the University of Crete, focusing on the development of biosensors, and her Master of Science (MSc) in Biomolecular Sciences from the Vrije Universiteit Amsterdam in Molecular biology.
Karin Jaymes is a co-founder of Xsensio, providing finance and accounting support. She is the manager at EPFL Nanolab, where she is in charge of the financial and administrative management of research projects, and administrative manager of the FET Flagship Pilot Guardian Angels that includes more than 40 partners from 13 European countries. Karin completed a summer course on Corporate Governance at Harvard in 2012.
Yann is working on the development and optimization of biological assays on the Lab-on-Skin™ sensing platform. He earned a MSc in Life Sciences and Technologies, with a specialization in Oncology and Molecular Medicine, from EPFL. Before joining Xsensio, Yann worked as a biochemical engineer at Abionic.
Raphaël is working on the development of Xsensio’s microfluidic platform. He earned a MSc in Life Sciences and Technologies, with a specialization in regenerative medicine and biomedical engineering, from EPFL. Before joining Xsensio, Raphaël worked in R&D at Nestlé.
Sorina is managing Quality Affairs / Regulatory Affairs at Xsensio. She She holds a PhD in Chemistry from EPFL.
Sadegh is working on the development of Xsensio’s microfabrication. He completed his PhD at EPFL in Electrical and Electronics Engineering.
Jacqueline is the Chair of the Board of Xsensio. She is a General Partner at Privilège Ventures, a VC that invests in seed and early stage companies in industrial Tech, MedTech, Wearables and ICT.
Nicola brings more than 20 years experience in life sciences, biotech and diagnostic industries in leading roles (VP Regional Marketing QIAGEN; VP Talent Management QIAGEN; Managing Director QIAGEN Ltd; VP Immunosystems Dynal Biotech (now part of ThermoFisher); Marketing & Business Development Manager Promega; NED for Biostatus Ltd).
Nicola brings more than 20 years experience in life sciences, biotech and diagnostic industries in leading roles (VP Regional Marketing QIAGEN; VP Talent Management QIAGEN; Managing Director QIAGEN Ltd; VP Immunosystems Dynal Biotech (now part of ThermoFisher); Marketing & Business Development Manager Promega; NED for Biostatus Ltd).
Adrian brings cutting-edge know-how and expertise to Xsensio, has played an instrumental role in the development of the FET core sensing technology that Xsensio is leveraging. He is a full Professor at EPFL, where he leads the Nanolab. He received his Ph.D. degree from the National Polytechnic Institute of Grenoble in France, and has held staff and/or visiting positions at LETI-CEA and LPCS-ENSER in Grenoble, at Stanford University, and at Tokyo Tech. He has published more than 350 articles in international journals and conference.
Esmeralda has several years of experience as manager at Boston-based investment firm Commons Capital where she was in charge of screening investment opportunities in a partnership with the Bill and Melinda Gates Foundation. She earned her MBA at the Massachusetts Institute of Technology (MIT), a B.S. and M.S. in Economics from ULB, Belgium and an executive degree in management from EPFL. Her past innovations have been awarded the MIT IDEAS International Technology Award, the MIT IDEAS Graduate Student Award and the Harvard Catalyst Grant.
Dr. Ayan Sen is the Department Chair, Critical Care Medicine at Mayo Clinic Scottsdale. Prior to his leading role, Dr. Ayan Sen was a Post-Doc fellow in the Department of Critical Care Medicine at the University of Pittsburgh Medical Center.
Prof. Lucas Liaudet is the vice head of the ICU at the CHUV and is responsible for the hemodynamic and cardiovascular sections of the service. He holds a position of full professor in pathophysiology at the Medical Faculty of the University of Lausanne, with particular emphasis on cardiovascular and respiratory pathophysiology. He is a recognized expert in the field, with an important publication record both in clinical and experimental circulatory shock, as well as in the evaluation of the microcirculation using Laser Doppler flowmetry.
Bracken Darrell is the president and CEO of Logitech. Prior to joining Logitech, he was executive vice president of Whirlpool Corporation and president of Whirlpool EMEA, where he guided the company through the economic downturn of 2008. Previously, Bracken was with Procter & Gamble, most recently as the president of Braun, the home appliance business. In addition to a total of twelve years with Procter & Gamble – in executive management positions as well as earlier years in brand management – Mr. Darrell served with General Electric Company for five years, most recently as the general manager of Consumer Home Service. Mr. Darrell began his career with Arthur Anderson and then PepsiCo. He holds an MBA degree from Harvard Business School and a B.A. degree in English from Hendrix College in Arkansas.
Pr. Denis Hochstrasser was Vice-Rector/ Vice President of Geneva University, in charge of Campus Biotech, the link between the University and the Hospitals, Personalized Health and the Information and Communication Technology Sector. He was also chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital. He is a Board certified physician in internal medicine & in clinical chemistry. At the academic level, he is Emeritus Professor both to Geneva’s Department of Human Protein Sciences, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. He was one of the founders of the Swiss Institute for Bioinformatics, of the Swiss Centre for Applied Human Toxicology and of Biobank Swiss Foundation, and a member of the CTI / KTI committee. He is a board member of Viollier laboratories, and a scientific founder of Geneva Proteomics Inc, Geneva Bioinformatics SA and Eclosion SA. He is an individual member of the Senate of the Swiss Academy of Medical Sciences.
info@xsensio.com
Sign up to get reports of our most recent activity.
